STOCK TITAN
  1. Home
  2. Sec-filings
  3. VNRX
  4. [Form 4] VOLITIONRX LTD Insider Trading Activity

VolitionRx (VNRX) executive receives 173,000 RSUs instead of cash pay

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Kway Jasmine reported acquisition or exercise transactions in this Form 4 filing.

VolitionRx Ltd executive Jasmine Kway reported an equity compensation grant. On February 26, 2026, she was awarded 173,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan in lieu of cash compensation otherwise owed.

The RSUs will be earned in twelve approximately equal monthly installments starting March 1, 2026, and then are subject to additional time-based vesting in a single installment on February 26, 2027, contingent on her continued service. Upon vesting and settlement, she will receive one share of common stock for each RSU that has been earned and vested.

Positive

  • None.

Negative

  • None.
Insider Kway Jasmine
Role CEO - Singapore Volition
Type Security Shares Price Value
Grant/Award Common Stock 173,000 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 418,614 shares (Direct); Common Stock — 10,400 shares (Indirect, By Spouse)
Footnotes (1)
  1. [object Object]
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kway Jasmine
(Last) (First) (Middle)
1489 WEST WARM SPRINGS ROAD
SUITE 110
(Street)
HENDERSON NV 89014
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
VOLITIONRX LTD [ VNRX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CEO - Singapore Volition
3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/26/2026 A 173,000(1) A $0 418,614 D
Common Stock 10,400 I By Spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. On February 26, 2026, the reporting person was awarded 173,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.
Remarks:
/s/ Jasmine Kway 02/27/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did VolitionRx (VNRX) report for Jasmine Kway?

VolitionRx reported that executive Jasmine Kway received a grant of 173,000 restricted stock units as equity compensation. These RSUs replace cash compensation and will convert into common shares only after specified earning and vesting dates are satisfied through continued service.

How many restricted stock units did Jasmine Kway receive from VolitionRx (VNRX)?

Jasmine Kway was awarded 173,000 restricted stock units under VolitionRx’s 2024 Stock Incentive Plan. The RSUs are structured as compensation in lieu of cash and will eventually settle into an equal number of common shares once all earning and vesting conditions are met.

How do the VolitionRx (VNRX) RSUs granted to Jasmine Kway vest and earn?

The 173,000 RSUs will be earned in twelve approximately equal monthly installments beginning March 1, 2026. After earning, they remain subject to additional time-based vesting in a single installment on February 26, 2027, requiring Ms. Kway’s continued service through those dates.

Why did VolitionRx (VNRX) grant RSUs to Jasmine Kway instead of cash?

VolitionRx granted 173,000 RSUs to Jasmine Kway in lieu of cash compensation that would otherwise have been owed. This structure shifts part of her pay into equity, aligning compensation with company performance through future stock settlement once the RSUs are earned and vested.

When will Jasmine Kway receive VolitionRx (VNRX) common shares from these RSUs?

Jasmine Kway will receive VolitionRx common shares only upon vesting and settlement of the RSUs. After monthly earning from March 1, 2026 and final time-based vesting on February 26, 2027, each earned and vested RSU will convert into one share of common stock.

What ownership does the Form 4 show for Jasmine Kway and her spouse in VolitionRx (VNRX)?

The Form 4 shows Jasmine Kway with directly held common stock and an additional indirect holding of 10,400 common shares held by her spouse. The RSU award will increase her potential future stock holdings once the units are both earned and fully vested.